231 related articles for article (PubMed ID: 30728439)
1. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.
Passweg JR; Baldomero H; Basak GW; Chabannon C; Corbacioglu S; Duarte R; Kuball J; Lankester A; Montoto S; de Latour RP; Snowden JA; Styczynski J; Yakoub-Agha I; Arat M; Mohty M; Kröger N;
Bone Marrow Transplant; 2019 Oct; 54(10):1575-1585. PubMed ID: 30728439
[TBL] [Abstract][Full Text] [Related]
2. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.
Passweg JR; Baldomero H; Chabannon C; Basak GW; Corbacioglu S; Duarte R; Dolstra H; Lankester AC; Mohty M; Montoto S; Peffault de Latour R; Snowden JA; Styczynski J; Yakoub-Agha I; Kröger N;
Bone Marrow Transplant; 2020 Aug; 55(8):1604-1613. PubMed ID: 32066864
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years.
Passweg JR; Baldomero H; Chabannon C; Basak GW; de la Cámara R; Corbacioglu S; Dolstra H; Duarte R; Glass B; Greco R; Lankester AC; Mohty M; Peffault de Latour R; Snowden JA; Yakoub-Agha I; Kröger N;
Bone Marrow Transplant; 2021 Jul; 56(7):1651-1664. PubMed ID: 33623153
[TBL] [Abstract][Full Text] [Related]
4. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report.
Passweg JR; Baldomero H; Bader P; Basak GW; Bonini C; Duarte R; Dufour C; Kröger N; Kuball J; Lankester A; Montoto S; Nagler A; Snowden JA; Styczynski J; Mohty M;
Bone Marrow Transplant; 2018 Sep; 53(9):1139-1148. PubMed ID: 29540849
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.
Passweg JR; Baldomero H; Bader P; Bonini C; Cesaro S; Dreger P; Duarte RF; Dufour C; Kuball J; Farge-Bancel D; Gennery A; Kröger N; Lanza F; Nagler A; Sureda A; Mohty M
Bone Marrow Transplant; 2016 Jun; 51(6):786-92. PubMed ID: 26901709
[TBL] [Abstract][Full Text] [Related]
6. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey.
Passweg JR; Baldomero H; Chabannon C; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; Mohty M; Neven B; Peffault de Latour R; Perić Z; Snowden JA; Yakoub-Agha I; Sureda A; Kröger N;
Bone Marrow Transplant; 2022 May; 57(5):742-752. PubMed ID: 35194156
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.
Passweg JR; Baldomero H; Ciceri F; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; McLornan DP; Neven B; de Latour RP; Perić Z; Ruggeri A; Snowden JA; Sureda A
Bone Marrow Transplant; 2023 Jun; 58(6):647-658. PubMed ID: 36879108
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell transplantation in Europe 1998.
Gratwohl A; Passweg J; Baldomero H; Hermans J; Urbano-Ispizua A;
Hematol J; 2000; 1(5):333-50. PubMed ID: 11920211
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).
Aljurf M; Nassar A; Hamidieh AA; Elhaddad A; Hamladji RM; Bazarbachi A; Ibrahim A; Ben Othman T; Abdel-Rahman F; Alseraihy A; Fahmy O; Hussein AA; Alabdulaaly A; Adil S; Alkindi SS; Bayoumy M; Dennison D; Bekadja MA; Redhouane AN; Rasheed W; AlSagheir A; Alsudairy R; Ladeb S; Benchekroun S; Ramzi M; Ahmed P; ElSolh H; Ahmed SO; Hussain F; Ghavamzadeh A
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):167-75. PubMed ID: 26452331
[TBL] [Abstract][Full Text] [Related]
10. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey.
Gratwohl A; Baldomero H; Passweg J; Urbano-Ispizua A;
Bone Marrow Transplant; 2002 Dec; 30(12):813-31. PubMed ID: 12476273
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. EBMT activity survey 2004 and changes in disease indication over the past 15 years.
Gratwohl A; Baldomero H; Frauendorfer K; Urbano-Ispizua A; ;
Bone Marrow Transplant; 2006 Jun; 37(12):1069-85. PubMed ID: 16757972
[TBL] [Abstract][Full Text] [Related]
13. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.
Passweg JR; Baldomero H; Ciceri F; de la Cámara R; Glass B; Greco R; Hazenberg MD; Kalwak K; McLornan DP; Neven B; Perić Z; Risitano AM; Ruggeri A; Snowden JA; Sureda A
Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38438647
[TBL] [Abstract][Full Text] [Related]
15. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
[TBL] [Abstract][Full Text] [Related]
16. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products.
Gratwohl A; Baldomero H; Frauendorfer K; Rocha V; Apperley J; Niederwieser D; ;
Bone Marrow Transplant; 2008 Apr; 41(8):687-705. PubMed ID: 18084334
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic cell transplantation for nonmalignant disorders.
Tolar J; Mehta PA; Walters MC
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S166-71. PubMed ID: 22226101
[TBL] [Abstract][Full Text] [Related]
18. Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012.
Correa C; Gonzalez-Ramella O; Baldomero H; Basquiera AL; Baena R; Arcuri L; Puga B; Rosales C; Chávez M; Hernández C; Maldonado B; Gómez-De León A; Mendoza N; Frutos C; Aranda L; Díaz L; Hernández M; Seber A; Karduss A; Jaimovich G; Martínez-Rolon J; Bonfim C; Greinix H; Koh MBC; Aljurf M; Iida M; Saber W; Niederwieser D; Atsuta Y; Galeano S; ;
Bone Marrow Transplant; 2022 Jun; 57(6):881-888. PubMed ID: 35347244
[TBL] [Abstract][Full Text] [Related]
19. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003.
Gratwohl A; Baldomero H; Schmid O; Horisberger B; Bargetzi M; Urbano-Ispizua A
Bone Marrow Transplant; 2005 Oct; 36(7):575-90. PubMed ID: 16086045
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic cell transplantation for benign hematological disorders and solid tumors.
Storb RF; Lucarelli G; McSweeney PA; Childs RW
Hematology Am Soc Hematol Educ Program; 2003; ():372-97. PubMed ID: 14633791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
